Jianglin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianglin Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Yiwen Wang
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
6 shared publications - Feng Huang
Department of Cardiology & Guangxi Key Laboratory Base of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention & Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
5 shared publications - Jian Zhu
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
5 shared publications - Lidong Hu
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
4 shared publications - Xiaojian Ji
Department of Rheumatology, Chinese PLA General Hospital, Beijing, China
4 shared publications - Jinshui Yang
Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1)
High‐Titer Antinuclear Antibody Defines a Distinct IgG4‐Related Disease Subset With Predilection for Lung and Kidney Involvement
Objective: This study investigated whether antinuclear antibody (ANA) positivity identifies a distinct clinical phenotype in IgG4‐related disease (IgG4‐RD), characterized by specific organ involvement patterns. Methods: We conducted a cohort study of patients diagnosed with IgG4‐RD (2016–2024). Based on indirect immunofluorescence (IIF) results, patients were categorized as ANA‐negative (titer ≤ 1:100) or ANA‐positive, with the latter further stratified by titer: group 1 (moderate titer, 1:320) and group 2 (high titer, ≥1:1000). We comprehensively compared demographics, organ involvement, and laboratory profiles across groups. Multivariable logistic regression was used to quantify associations. Results: Among 278 patients, 38 (13.7%) were ANA‐positive ( n = 19 per titer‐based subgroup). ANA patterns differed: granular in group 1 versus homogeneous/granular homogeneous in group 2. Only patients in group 2 (high‐titer ANA) demonstrated a significantly elevated risk of lung and kidney initial onset and involvement compared to ANA‐negative patients. This group also exhibited marked hypocomplementemia. The adjusted odds ratios for lung and kidney involvement in group 2 were 10.18 (95% CI: 3.590–28.876) and 4.42 (95% CI: 1.605–12.151), respectively. No such associations were found in group 1. Conclusion: IgG4‐RD combined with high‐titer ANA (≥1:1000), mainly presenting as homogeneous type or homogeneous granular type, characterized by a heightened propensity for lung and kidney, initial onset and involvement, and hypocomplementemia. Routine ANA testing and careful assessment of pulmonary and renal systems are warranted in these patients.
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1)
Open AccessHigh‐Titer Antinuclear Antibody Defines a Distinct IgG4‐Related Disease Subset With Predilection for Lung and Kidney Involvement
Objective: This study investigated whether antinuclear antibody (ANA) positivity identifies a distinct clinical phenotype in IgG4‐related disease (IgG4‐RD), characterized by specific organ involvement patterns. Methods: We conducted a cohort study of patients diagnosed with IgG4‐RD (2016–2024). Based on indirect immunofluorescence (IIF) results, patients were categorized as ANA‐negative (titer ≤ 1:100) or ANA‐positive, with the latter further stratified by titer: group 1 (moderate titer, 1:320) and group 2 (high titer, ≥1:1000). We comprehensively compared demographics, organ involvement, and laboratory profiles across groups. Multivariable logistic regression was used to quantify associations. Results: Among 278 patients, 38 (13.7%) were ANA‐positive ( n = 19 per titer‐based subgroup). ANA patterns differed: granular in group 1 versus homogeneous/granular homogeneous in group 2. Only patients in group 2 (high‐titer ANA) demonstrated a significantly elevated risk of lung and kidney initial onset and involvement compared to ANA‐negative patients. This group also exhibited marked hypocomplementemia. The adjusted odds ratios for lung and kidney involvement in group 2 were 10.18 (95% CI: 3.590–28.876) and 4.42 (95% CI: 1.605–12.151), respectively. No such associations were found in group 1. Conclusion: IgG4‐RD combined with high‐titer ANA (≥1:1000), mainly presenting as homogeneous type or homogeneous granular type, characterized by a heightened propensity for lung and kidney, initial onset and involvement, and hypocomplementemia. Routine ANA testing and careful assessment of pulmonary and renal systems are warranted in these patients.
- Open Access
Clinical and genetic determinants of worse sexual experience in male patients with radiographic axial spondyloarthritis: a multimodal study
Objective: The expression and experience of sexuality is a key part of an individual’s self-identity, yet it is often overlooked in clinical settings. This study aims to evaluate the impact of radiographic axial spondyloarthritis (r-axSpA) on sexual experience in male patients, identify contributing factors and explore the potential causal relationship between r-axSpA and erectile dysfunction (ED). Methods: We assessed the sexual experience of 113 male patients with r-axSpA and 73 healthy people using the Sexual Experience Questionnaire in the cross-sectional study. Linear regression analysis was used to explore the contributions of clinical factors to worse sexual experience. A two-sample Mendelian randomisation (MR) design was conducted to examine the potential causal association of r-axSpA with the risk of ED. Results: There was a significant difference in the total sexual experience score between patients with r-axSpA and healthy controls (41.81±8.71 vs 50.23±8.82, p<0.001). Patients with r-axSpA had a worse score in all dimensions of sexual experience, including erectile function, individual satisfaction and couple satisfaction, compared with healthy individuals. In the regression model adjusted for age, disease duration and body mass index, disease activity (Bath Ankylosing Spondylitis Disease Activity Index), physical function (Bath Ankylosing Spondylitis Functional Index), mobility (Bath Ankylosing Spondylitis Metrology Index, chest expansion and finger-floor distance), health index (Assessment of SpondyloArthritis international Society Health Index), sleep quality (Pittsburgh Sleep Quality Index) and psychological status (Hospital Anxiety and Depression Scale (HADS), HADS-Anxiety and HADS-Depression) were significant determinants of sexual experience. The two-sample MR analysis demonstrated no causal effect of r-axSpA on the risk of ED (OR: 0.973; 95% CI: 0.824 to 1.149; p=0.749) based on the inverse variance weighted method. Sensitivity analyses supported the result, with no evidence of directional pleiotropy. Conclusions: Worse sexual experience was associated with increased disease activity, reduced mobility, lower health index, poor sleep quality and psychological status. Genetic-level evidence indicated no direct causal relationship between r-axSpA and ED. Therefore, actively assessing disease-related suffering and developing new management strategies are essential for improving sexual experience in patients with r-axSpA.
Open AccessClinical and genetic determinants of worse sexual experience in male patients with radiographic axial spondyloarthritis: a multimodal study
Objective: The expression and experience of sexuality is a key part of an individual’s self-identity, yet it is often overlooked in clinical settings. This study aims to evaluate the impact of radiographic axial spondyloarthritis (r-axSpA) on sexual experience in male patients, identify contributing factors and explore the potential causal relationship between r-axSpA and erectile dysfunction (ED). Methods: We assessed the sexual experience of 113 male patients with r-axSpA and 73 healthy people using the Sexual Experience Questionnaire in the cross-sectional study. Linear regression analysis was used to explore the contributions of clinical factors to worse sexual experience. A two-sample Mendelian randomisation (MR) design was conducted to examine the potential causal association of r-axSpA with the risk of ED. Results: There was a significant difference in the total sexual experience score between patients with r-axSpA and healthy controls (41.81±8.71 vs 50.23±8.82, p<0.001). Patients with r-axSpA had a worse score in all dimensions of sexual experience, including erectile function, individual satisfaction and couple satisfaction, compared with healthy individuals. In the regression model adjusted for age, disease duration and body mass index, disease activity (Bath Ankylosing Spondylitis Disease Activity Index), physical function (Bath Ankylosing Spondylitis Functional Index), mobility (Bath Ankylosing Spondylitis Metrology Index, chest expansion and finger-floor distance), health index (Assessment of SpondyloArthritis international Society Health Index), sleep quality (Pittsburgh Sleep Quality Index) and psychological status (Hospital Anxiety and Depression Scale (HADS), HADS-Anxiety and HADS-Depression) were significant determinants of sexual experience. The two-sample MR analysis demonstrated no causal effect of r-axSpA on the risk of ED (OR: 0.973; 95% CI: 0.824 to 1.149; p=0.749) based on the inverse variance weighted method. Sensitivity analyses supported the result, with no evidence of directional pleiotropy. Conclusions: Worse sexual experience was associated with increased disease activity, reduced mobility, lower health index, poor sleep quality and psychological status. Genetic-level evidence indicated no direct causal relationship between r-axSpA and ED. Therefore, actively assessing disease-related suffering and developing new management strategies are essential for improving sexual experience in patients with r-axSpA.
- Open Access
- 18 January 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (1) , e29703
Adherence, Efficacy, and Safety of Wearable Technology–Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial
Background: Clinical practice guidelines recommend that exercise is essential in the self-management of ankylosing spondylitis (AS). Attending supervised interventions requiring periodic medical center visits can be difficult and patients may decline participation, whereas effective home-based exercise interventions that do not require regular medical center visits are likely to be more accessible for AS patients. Objective: The goal of the research was to investigate the adherence, efficacy, and safety of a wearable technology–assisted combined home-based exercise program in AS. Methods: This was a 16-week investigator-initiated, assessor-blinded, randomized, pilot controlled trial conducted at Chinese People’s Liberation Army General Hospital. We enrolled patients with AS who had no regular exercise habits and had been stable in drug treatment for the preceding month. Patients were randomly assigned (1:1) using a computer algorithm. An exercise program consisting of moderate-intensity aerobic exercise and functional exercise was given to the patients in the intervention group. The exercise intensity was controlled by a Mio FUSE Heart Rate Monitor wristband, which uses photoplethysmography to measure heart rate. Patients in the control group received usual care. The primary outcome was the difference in the Ankylosing Spondylitis Disease Activity Score (ASDAS). The secondary outcomes were patient global assessment (PGA), physician global assessment (PhGA), total pain, nocturnal pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BAS Functional Index (BASFI), BAS Metrology Index (BASMI), Spondyloarthritis International Society Health Index (ASAS HI), 36-item Short Form Survey (SF-36), maximal oxygen uptake (VO2) max, body composition, range of motion of joints, and muscle endurance tests. Retention rate, adherence rate, barriers to being active, and adverse events were also assessed. Results: A total of 77 patients were screened, of whom 55 (71%) patients were enrolled; 2% (1/55) withdrew without treatment after randomization. Patients were assigned to the intervention (n=26) or control group (n=28). The median adherence rate of the prescribed exercise protocol was 84.2% (IQR 48.7%-97.9%). For the primary outcome, between-group difference of ASDAS was significant, favoring the intervention (–0.2, 95% CI –0.4 to 0.02, P=.03). For the secondary outcomes, significant between-group differences at 16 weeks were detected in PGA, PhGA, total pain, BASDAI, BASDAI-fatigue, BASDAI–spinal pain, BASDAI–morning stiffness intensity, BASFI, and BASMI. Moreover, the frequency of difficulty in ASAS HI-motivation at 16 weeks was less in the intervention group (P=.03). Between-group difference for change from baseline were also detected in VO2 max, SF-36, back extensor endurance test, and the range of motion of cervical lateral flexion at 16 weeks. Lack of time, energy, and willpower were the most distinct barriers to being active. Incidences of adverse events were similar between groups (P=.11). Conclusions: Our pilot study suggests that this technology-assisted combined home-based exercise program can improve the clinical outcomes of patients with AS who have no exercise habit, with good adherence and safety profile. Trial Registration: Chinese Clinical Trial Registry ChiCTR1900024244; http://www.chictr.org.cn/showproj.aspx?proj=40176
- 18 January 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (1) , e29703
Open AccessAdherence, Efficacy, and Safety of Wearable Technology–Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial
Background: Clinical practice guidelines recommend that exercise is essential in the self-management of ankylosing spondylitis (AS). Attending supervised interventions requiring periodic medical center visits can be difficult and patients may decline participation, whereas effective home-based exercise interventions that do not require regular medical center visits are likely to be more accessible for AS patients. Objective: The goal of the research was to investigate the adherence, efficacy, and safety of a wearable technology–assisted combined home-based exercise program in AS. Methods: This was a 16-week investigator-initiated, assessor-blinded, randomized, pilot controlled trial conducted at Chinese People’s Liberation Army General Hospital. We enrolled patients with AS who had no regular exercise habits and had been stable in drug treatment for the preceding month. Patients were randomly assigned (1:1) using a computer algorithm. An exercise program consisting of moderate-intensity aerobic exercise and functional exercise was given to the patients in the intervention group. The exercise intensity was controlled by a Mio FUSE Heart Rate Monitor wristband, which uses photoplethysmography to measure heart rate. Patients in the control group received usual care. The primary outcome was the difference in the Ankylosing Spondylitis Disease Activity Score (ASDAS). The secondary outcomes were patient global assessment (PGA), physician global assessment (PhGA), total pain, nocturnal pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BAS Functional Index (BASFI), BAS Metrology Index (BASMI), Spondyloarthritis International Society Health Index (ASAS HI), 36-item Short Form Survey (SF-36), maximal oxygen uptake (VO2) max, body composition, range of motion of joints, and muscle endurance tests. Retention rate, adherence rate, barriers to being active, and adverse events were also assessed. Results: A total of 77 patients were screened, of whom 55 (71%) patients were enrolled; 2% (1/55) withdrew without treatment after randomization. Patients were assigned to the intervention (n=26) or control group (n=28). The median adherence rate of the prescribed exercise protocol was 84.2% (IQR 48.7%-97.9%). For the primary outcome, between-group difference of ASDAS was significant, favoring the intervention (–0.2, 95% CI –0.4 to 0.02, P=.03). For the secondary outcomes, significant between-group differences at 16 weeks were detected in PGA, PhGA, total pain, BASDAI, BASDAI-fatigue, BASDAI–spinal pain, BASDAI–morning stiffness intensity, BASFI, and BASMI. Moreover, the frequency of difficulty in ASAS HI-motivation at 16 weeks was less in the intervention group (P=.03). Between-group difference for change from baseline were also detected in VO2 max, SF-36, back extensor endurance test, and the range of motion of cervical lateral flexion at 16 weeks. Lack of time, energy, and willpower were the most distinct barriers to being active. Incidences of adverse events were similar between groups (P=.11). Conclusions: Our pilot study suggests that this technology-assisted combined home-based exercise program can improve the clinical outcomes of patients with AS who have no exercise habit, with good adherence and safety profile. Trial Registration: Chinese Clinical Trial Registry ChiCTR1900024244; http://www.chictr.org.cn/showproj.aspx?proj=40176
- Open Access
- 15 December 2021
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (15) , 1864-1866
Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
An abstract is unavailable. This article is available as a PDF only.
- 15 December 2021
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (15) , 1864-1866
Open AccessSystemic lupus erythematosus following human papillomavirus 9-valent vaccination
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 17 April 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Adherence, Efficacy, and Safety of Wearable Technology–Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial (Preprint)
BACKGROUND Clinical practice guidelines recommend that exercise is essential in the self-management of ankylosing spondylitis (AS). Attending supervised interventions requiring periodic medical center visits can be difficult and patients may decline participation, whereas effective home-based exercise interventions that do not require regular medical center visits are likely to be more accessible for AS patients. OBJECTIVE The goal of the research was to investigate the adherence, efficacy, and safety of a wearable technology–assisted combined home-based exercise program in AS. METHODS This was a 16-week investigator-initiated, assessor-blinded, randomized, pilot controlled trial conducted at Chinese People’s Liberation Army General Hospital. We enrolled patients with AS who had no regular exercise habits and had been stable in drug treatment for the preceding month. Patients were randomly assigned (1:1) using a computer algorithm. An exercise program consisting of moderate-intensity aerobic exercise and functional exercise was given to the patients in the intervention group. The exercise intensity was controlled by a Mio FUSE Heart Rate Monitor wristband, which uses photoplethysmography to measure heart rate. Patients in the control group received usual care. The primary outcome was the difference in the Ankylosing Spondylitis Disease Activity Score (ASDAS). The secondary outcomes were patient global assessment (PGA), physician global assessment (PhGA), total pain, nocturnal pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BAS Functional Index (BASFI), BAS Metrology Index (BASMI), Spondyloarthritis International Society Health Index (ASAS HI), 36-item Short Form Survey (SF-36), maximal oxygen uptake (VO2) max, body composition, range of motion of joints, and muscle endurance tests. Retention rate, adherence rate, barriers to being active, and adverse events were also assessed. RESULTS A total of 77 patients were screened, of whom 55 (71%) patients were enrolled; 2% (1/55) withdrew without treatment after randomization. Patients were assigned to the intervention (n=26) or control group (n=28). The median adherence rate of the prescribed exercise protocol was 84.2% (IQR 48.7%-97.9%). For the primary outcome, between-group difference of ASDAS was significant, favoring the intervention (–0.2, 95% CI –0.4 to 0.02, P=.03). For the secondary outcomes, significant between-group differences at 16 weeks were detected in PGA, PhGA, total pain, BASDAI, BASDAI-fatigue, BASDAI–spinal pain, BASDAI–morning stiffness intensity, BASFI, and BASMI. Moreover, the frequency of difficulty in ASAS HI-motivation at 16 weeks was less in the intervention group (P=.03). Between-group difference for change from baseline were also detected in VO2 max, SF-36, back extensor endurance test, and the range of motion of cervical lateral flexion at 16 weeks. Lack of time, energy, and willpower were the most distinct barriers to being active. Incidences of adverse events were similar between groups (P=.11). CONCLUSIONS Our pilot study suggests that this technology-assisted combined home-based exercise program can improve the clinical outcomes of patients with AS who have no exercise habit, with good adherence and safety profile. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR1900024244; http://www.chictr.org.cn/showproj.aspx?proj=40176
- 17 April 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAdherence, Efficacy, and Safety of Wearable Technology–Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial (Preprint)
BACKGROUND Clinical practice guidelines recommend that exercise is essential in the self-management of ankylosing spondylitis (AS). Attending supervised interventions requiring periodic medical center visits can be difficult and patients may decline participation, whereas effective home-based exercise interventions that do not require regular medical center visits are likely to be more accessible for AS patients. OBJECTIVE The goal of the research was to investigate the adherence, efficacy, and safety of a wearable technology–assisted combined home-based exercise program in AS. METHODS This was a 16-week investigator-initiated, assessor-blinded, randomized, pilot controlled trial conducted at Chinese People’s Liberation Army General Hospital. We enrolled patients with AS who had no regular exercise habits and had been stable in drug treatment for the preceding month. Patients were randomly assigned (1:1) using a computer algorithm. An exercise program consisting of moderate-intensity aerobic exercise and functional exercise was given to the patients in the intervention group. The exercise intensity was controlled by a Mio FUSE Heart Rate Monitor wristband, which uses photoplethysmography to measure heart rate. Patients in the control group received usual care. The primary outcome was the difference in the Ankylosing Spondylitis Disease Activity Score (ASDAS). The secondary outcomes were patient global assessment (PGA), physician global assessment (PhGA), total pain, nocturnal pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BAS Functional Index (BASFI), BAS Metrology Index (BASMI), Spondyloarthritis International Society Health Index (ASAS HI), 36-item Short Form Survey (SF-36), maximal oxygen uptake (VO2) max, body composition, range of motion of joints, and muscle endurance tests. Retention rate, adherence rate, barriers to being active, and adverse events were also assessed. RESULTS A total of 77 patients were screened, of whom 55 (71%) patients were enrolled; 2% (1/55) withdrew without treatment after randomization. Patients were assigned to the intervention (n=26) or control group (n=28). The median adherence rate of the prescribed exercise protocol was 84.2% (IQR 48.7%-97.9%). For the primary outcome, between-group difference of ASDAS was significant, favoring the intervention (–0.2, 95% CI –0.4 to 0.02, P=.03). For the secondary outcomes, significant between-group differences at 16 weeks were detected in PGA, PhGA, total pain, BASDAI, BASDAI-fatigue, BASDAI–spinal pain, BASDAI–morning stiffness intensity, BASFI, and BASMI. Moreover, the frequency of difficulty in ASAS HI-motivation at 16 weeks was less in the intervention group (P=.03). Between-group difference for change from baseline were also detected in VO2 max, SF-36, back extensor endurance test, and the range of motion of cervical lateral flexion at 16 weeks. Lack of time, energy, and willpower were the most distinct barriers to being active. Incidences of adverse events were similar between groups (P=.11). CONCLUSIONS Our pilot study suggests that this technology-assisted combined home-based exercise program can improve the clinical outcomes of patients with AS who have no exercise habit, with good adherence and safety profile. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR1900024244; http://www.chictr.org.cn/showproj.aspx?proj=40176
- Open Access
- 25 February 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-11
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Objectives. Ankylosing spondylitis (AS) is a chronic disease that decreases mobility, function, and quality of life. This study introduced the “Smart-phone SpondyloArthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool designed for AS/spondyloarthritis (SpA) disease management and used SpAMS data to evaluate clinical characteristics of Chinese patients with AS. Methods. SpAMS integrates patient’s and physician’s portals in a smart phone application. The Chinese Ankylosing Spondylitis Prospective Imaging Cohort was launched using SpAMS in April 2016. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatments were recorded by rheumatologists during each visit. Results. In total, 1201 patients with AS [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. Mean (SD) disease duration was 8.4 (6.1) years. Past or current symptoms of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of patients, respectively. AAU and IBD occurred significantly more in patients with symptom duration > 10 years. The most commonly used medications at baseline were nonsteroidal anti-inflammatory drugs (98.2%). Patients using tumour necrosis factor inhibitors accounted for 20.8%, and 66.4% of patients used conventional synthetic disease-modifying antirheumatic drugs. At baseline, 57.2% of patients had inactive disease (ID)/low disease activity (LDA); this rate significantly improved to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). Problems solved in SpAMS caused 29.1% of clinic visits to a tertiary hospital unnecessary. SpAMS saved an average of 5.3 hours and 327.4 RMB per person on traffic expenses; these expenses equalled 16% of the Chinese monthly disposable personal income. Conclusions. SpAMS is a time- and cost-saving disease management tool that can help patients with AS perform self-management and provide valuable data to clinicians.
- 25 February 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-11
Open AccessImprovement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Objectives. Ankylosing spondylitis (AS) is a chronic disease that decreases mobility, function, and quality of life. This study introduced the “Smart-phone SpondyloArthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool designed for AS/spondyloarthritis (SpA) disease management and used SpAMS data to evaluate clinical characteristics of Chinese patients with AS. Methods. SpAMS integrates patient’s and physician’s portals in a smart phone application. The Chinese Ankylosing Spondylitis Prospective Imaging Cohort was launched using SpAMS in April 2016. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatments were recorded by rheumatologists during each visit. Results. In total, 1201 patients with AS [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. Mean (SD) disease duration was 8.4 (6.1) years. Past or current symptoms of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of patients, respectively. AAU and IBD occurred significantly more in patients with symptom duration > 10 years. The most commonly used medications at baseline were nonsteroidal anti-inflammatory drugs (98.2%). Patients using tumour necrosis factor inhibitors accounted for 20.8%, and 66.4% of patients used conventional synthetic disease-modifying antirheumatic drugs. At baseline, 57.2% of patients had inactive disease (ID)/low disease activity (LDA); this rate significantly improved to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). Problems solved in SpAMS caused 29.1% of clinic visits to a tertiary hospital unnecessary. SpAMS saved an average of 5.3 hours and 327.4 RMB per person on traffic expenses; these expenses equalled 16% of the Chinese monthly disposable personal income. Conclusions. SpAMS is a time- and cost-saving disease management tool that can help patients with AS perform self-management and provide valuable data to clinicians.
- Open Access
- 30 September 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-phone Management System: A Prospective Cohort Study (Preprint)
BACKGROUND Ankylosing spondylitis (AS) is a chronic disease that mainly affects the axial skeleton, leading to decreased mobility, function, and quality of life. With the advent of mobile health (mHealth) technologies, it is now possible to create more economical, sustainable, and user-friendly communication and health monitoring systems to improve the effectiveness of patient care and to gather real-world clinical data for clinical research. OBJECTIVE To introduce “smart-phone Spondyloarthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool, specifically designed for longitudinal disease management and prospective ankylosing spondylitis (AS)/spondyloarthritis (SpA) and to evaluate the clinical profile of Chinese (AS) patients. METHODS SpAMS integrates the patient’s portal and the physician’s portal in a cell phone application. By using SpAMS, Chinese Ankylosing Spondylitis Prospective Imaging Cohort (CASPIC) was launched from April 2016. All patients fulfilled the 1984 modified New York criteria. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatment regimens were recorded by rheumatologists during each visit. RESULTS In total, 1201 AS patients [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. The mean (SD) disease duration was 8.4 (6.1) years. A history or current symptoms suggestive of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of the patients, respectively. AAU and IBD were found significantly more in patients with a symptom duration > 10 years (31.1%, 12.5%, respectively). At the baseline visit, the most commonly used medications were non-steroidal anti-inflammatory drugs (NSAIDs) (98.2%). Patients using tumor necrosis factor inhibitors (TNFi) accounted for 20.8% of enrolled patients. Additionally, 66.4% of patients used conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs). At baseline, the percentage of patients with inactive disease (ID)/low disease activity (LDA) was 57.2%, and this value improved significantly to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). By solving problems in SpAMS, 29.1% of clinic visits were unnecessary and therefore time had been saved. At least an average of 5.3 hours and 327.4 RMB per person spent on traffic was saved through SpAMS. The saved traffic expenses were equal to 16% of the Chinese monthly disposable personal income. CONCLUSIONS SpAMS is a time- and cost-saving disease management tool, helping AS patients perform self-management and providing valuable data to clinicians. This is the first nationwide real-world study of AS patients in China who use mHealth technology, and our results contribute significantly to characterizing the clinical profiles of Chinese patients with AS.
- 30 September 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImprovement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-phone Management System: A Prospective Cohort Study (Preprint)
BACKGROUND Ankylosing spondylitis (AS) is a chronic disease that mainly affects the axial skeleton, leading to decreased mobility, function, and quality of life. With the advent of mobile health (mHealth) technologies, it is now possible to create more economical, sustainable, and user-friendly communication and health monitoring systems to improve the effectiveness of patient care and to gather real-world clinical data for clinical research. OBJECTIVE To introduce “smart-phone Spondyloarthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool, specifically designed for longitudinal disease management and prospective ankylosing spondylitis (AS)/spondyloarthritis (SpA) and to evaluate the clinical profile of Chinese (AS) patients. METHODS SpAMS integrates the patient’s portal and the physician’s portal in a cell phone application. By using SpAMS, Chinese Ankylosing Spondylitis Prospective Imaging Cohort (CASPIC) was launched from April 2016. All patients fulfilled the 1984 modified New York criteria. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatment regimens were recorded by rheumatologists during each visit. RESULTS In total, 1201 AS patients [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. The mean (SD) disease duration was 8.4 (6.1) years. A history or current symptoms suggestive of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of the patients, respectively. AAU and IBD were found significantly more in patients with a symptom duration > 10 years (31.1%, 12.5%, respectively). At the baseline visit, the most commonly used medications were non-steroidal anti-inflammatory drugs (NSAIDs) (98.2%). Patients using tumor necrosis factor inhibitors (TNFi) accounted for 20.8% of enrolled patients. Additionally, 66.4% of patients used conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs). At baseline, the percentage of patients with inactive disease (ID)/low disease activity (LDA) was 57.2%, and this value improved significantly to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). By solving problems in SpAMS, 29.1% of clinic visits were unnecessary and therefore time had been saved. At least an average of 5.3 hours and 327.4 RMB per person spent on traffic was saved through SpAMS. The saved traffic expenses were equal to 16% of the Chinese monthly disposable personal income. CONCLUSIONS SpAMS is a time- and cost-saving disease management tool, helping AS patients perform self-management and providing valuable data to clinicians. This is the first nationwide real-world study of AS patients in China who use mHealth technology, and our results contribute significantly to characterizing the clinical profiles of Chinese patients with AS.